Sermorelin dosage

Sermorelin injectable dosage

Reported injectable protocols use 0.2–0.5 mg per administration, daily for 3-6 months. A reported bedtime progression uses 200 mcg in weeks 1–2, 300 mcg in weeks 3–4, 400 mcg in weeks 5–6 and 500 mcg from week 7. An alternative schedule uses a 3–6-month course; these are reported subcutaneous steps rather than nasal-spray directions.[1][2][8][9][3][4][5][11]

Sermorelin is a GHRH(1–29) analogue that stimulates pituitary GH secretion. Response depends on the underlying endocrine condition and pituitary function.[1][2][6]

Sermorelin intranasal dosage

Reported-use amounts for Sermorelin are ~100 mcg / spray, 5 nights / wk, on an ongoing basis.[10]

Nasal sermorelin is a formulation of the GHRH(1–29) analogue. Its delivered amount depends on the concentration and volume per spray, separately from an injection preparation.[7][2][6][1][10]

Frequency and timing

The injection pattern is timed before bed. The nasal pattern also lists bedtime use on five nights per week.[3][8][9][1][2][4][5][10]

Cycle length and breaks

Injectable: 3-6 months. Intranasal: Ongoing. Ongoing treatment does not follow a routine on/off cycle.[1][2][8][9][3][4][5][10]

Approval and product quality

Sermorelin is not an FDA-approved drug.[2]

Side effects and long-term safety

Local injection tolerance, flushing, headache, water retention and glucose or IGF-1 effects are relevant concerns. Pregnancy, active malignancy and sports restrictions also require attention.[2][1]

Route-specific dosing limits

Long-term unapproved GH-secretagogue use needs lab monitoring and careful exclusion of higher-risk contexts. Reported-use intranasal schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[2][1][11][10]